Status:
COMPLETED
Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
Lead Sponsor:
Britannia Pharmaceuticals Ltd.
Conditions:
Parkinson's Disease
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
PHASE3
Brief Summary
To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.
Eligibility Criteria
Inclusion
- 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day
Exclusion
- hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00346827
Start Date
July 1 2006
End Date
August 1 2007
Last Update
July 10 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.